Fiocruz Expects to Manufacture Vaccine for 130 Million Brazilians in 2021

Fiocruz has a technology transfer agreement with AstraZeneca, the pharmaceutical company developing the vaccine in partnership with Oxford University, to produce the immunizer on Brazilian soil.

RIO DE JANEIRO, BRAZIL - Fiocruz (Oswaldo Cruz Foundation) has an agreement with AstraZeneca, the pharmaceutical company developing the Oxford vaccine. Some 65 million people are expected to be immunized in Brazil in the first half of 2021 and another 65 million in the second half.

Fiocruz production and innovation vice-president, Marco Krieger said on Monday, November 23rd, in an interview to GloboNews, that the foundation intends to immunize 65 million people in the first half of 2021 and other 65 million in the second, considering the higher efficacy vaccine plan disclosed by Oxford University.

Fiocruz has a technology transfer . . .

To read the full NEWS and much more, Subscribe to our Premium Membership Plan. Already Subscribed?